by Nicolas Oberndorfer | May 26, 2021 | c-LEcta Corporate News, News
Corporate News back to the archive c-LEcta: European dossiers submitted for approval of new enzymes in the food industry Successful submission of two registration dossiers for food enzymes in Europe. Dossiers were prepared in exclusive collaboration with a partner in...
by Nicolas Oberndorfer | Mar 2, 2021 | c-LEcta Corporate News, News
Corporate news to the archive EXCiPACT certification for c-LEcta’s high production standards Certified by EXCiPACT, c-LEcta’s production and distribution quality standards exceed ISO 9001 requirements Certification is deemed an international seal of approval and...
by Nicolas Oberndorfer | Dec 15, 2020 | c-LEcta Corporate News, ESG-Friday
Corporate news to the archive c-LEcta continues its growth in 2020 and increases its EBITDA above average DENARASE is the most important growth driver with applications in gene and cell therapy as well as vaccine production Sales for 2020 to exceed the EUR 10 million...
by Nicolas Oberndorfer | Jul 28, 2020 | c-LEcta Corporate News, News
Corporate news to the archive c-LEcta expands collaboration with specialty medical logistics provider World Courier Cooperation with renowned specialty logistics service provider for the transport of sensitive products Seamless monitoring of global transport...
by Nicolas Oberndorfer | Jun 16, 2020 | c-LEcta Corporate News, News
Corporate news to the archive c-LEcta grows significantly in fiscal year 2019, strong start in 2020 Significant revenue growth of 114% compared to 2018, EBITDA slightly positive Product business further expanded and organizational growth driven forward Following...
by Nicolas Oberndorfer | Mar 10, 2020 | c-LEcta Corporate News, News
Corporate news to the archive c-LEcta takes on new industrial partner and successfully continues its development into a product company Expansion of cooperation with industry in the area of process development Cooperation with one of the world’s largest suppliers of...
